• About
  • People
  • Projects
  • Clinical Trials
  • Key Publications
  • Funding
  • Collaborations

Inflammation is the very complex set of immune pathways underlying the normal acute response to injury and infection. However, unresolved chronic inflammation is a key driver of degenerative diseases and cancer. Therefore, protective adjustment of inflammation requires molecular and functional characterisation of the master regulators, which control the delicate balance between health and disease.

The Liver Metastasis Research Group investigates the molecular and cellular immune mechanisms that determine the capacity of liver tissue to resist metastatic invasion. Our goal is to address the urgent medical needs of risk prediction, prevention, early detection, and treatment of liver metastases. Being a small group with a clear translational research focus on the development of predictive and therapeutic biomarkers, we apply a straightforward bed-to-bench-and-back approach to determine the beneficial/detrimental functions of key immune mediators in cancer patients with distinctive disease progression patterns.

 

Researchers

Alumni

2016: Dr Miriam Canavese, Scientific consultant, Imperial College, London, UK & SystemGenomics Ltd, was a visiting scientist.

LMRG: Honours Student Projects
  • Development of prognostic biomarkers of metastatic colorectal cancer.
  • HLA-G as predictive biomarker of response to therapy.
  • Imaging biomarkers for prediction of metastatic risk in colorectal cancer patients.
LMRG: Higher Degree Research Student Projects
  • Characterisation of the immune cell compartment in liver metastasis.
  • Development of targeted nanoparticles as preventative therapy for liver metastasis.

Development of diagnostic and prognostic biomarkers for screening and early detection of metastatic colorectal cancer.

HREC reference number: HREC/14/TQEHLMH/164

For more information please contact: Dr Ehud Hauben

Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages

Kirana C, Ruszkiewicz A, Stubbs RS, Hardingham JE, Hewett PJ, Maddern GJ, Hauben E. Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages. Int J Cancer; 2017. 140 (11): 2577-2586.

Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer

Canavese M, Ngo DT, Maddern GJ, Hardingham JE, Price TJ, Hauben E . Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. Int. J. Cancer; 2017. 140(10): 2183-2191.

Discordant frequencies of tissue-resident and circulating CD180-negative B cells in chronic rhinosinusitis

Miljkovic D, Ou J, Kirana C, Hulse KE, Hauben E, Psaltis A, Wormald PJ, Vreugde S . Discordant frequencies of tissue-resident and circulating CD180-negative B cells in chronic rhinosinusitis. Int. Forum Allergy Rhinol.; 2017. 7(6):609-614.

Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis

Canavese M, Wijesundara D, Maddern GJ, Grubor-Bauk B, Hauben E . Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis. Clin. Transl. Immunology; 2016. 5(10): 101-105.

Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review

Young JP, Win AK, Rosty C, Flight I, Roder D, Young GP, Frank O, Suthers GK, Hewett PJ, Ruszkiewicz A, Hauben E, Adelstein BA, Parry S, Townsend A, Hardingham JE, Price TJ. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J. Gastroenterol. Hepatol.; 2015. 30(1): 6-13.

Funding since 2016

Chief InvesigatorsGranting BodyProject TitleTotal Grant AmountFunding Period
Hauben E, Gowans E, Vreugde S, Evdokiou A, Maddern G
ARC Linkage, Infrastructure, Equipment and Facilities (LIEF) grantEquipment grant: Miltenyi AutoMACS Pro$30,0002016
Maddern G, Hauben H, Ngo D, Beltrame J
THRF: The Hospital Research Foundation Project GrantThe nexus between visceral adiposity, associated liver composition, and metastatic progression in colorectal cancer patients $75,0002016
Hauben E, Nicolas Voelcker N, Maddern GTHRF: The Hospital Research Foundation Project GrantDevelopment of targeted nanoparticles as preventative therapy for liver metastasis $125,0002017
CollaboratorPositionInstitutionCityCountry
Professor Nico VoelckerScientific Director of Melbourne Centre for Nanofabrication, Director of the Australian National Fabrication Facility's Victorian Node (ANFF-VIC), Science Leader at CSIRO and ProfessorMonash Institute of Pharmaceutical Sciences, Monash UniversityMelbourneAustralia
Dr Lifeng PengResearcher, Course Coordinator and LecturerProteomics, School of Biological Sciences, Victoria University of WellingtonWellingtonNew Zealand